MiniMed Group (MMED)
Builds integrated insulin-delivery and glucose-monitoring systems for diabetes care.
Something off on this page? Send us feedback.
Generates product revenue from connected diabetes-management systems—pumps, continuous glucose monitors, consumables, smart pens, software, and care services—with recurring supply use tied to its installed base. Runs a single operating segment under Medtronic’s controlling ownership.
Develops and sells integrated diabetes-management systems for people with diabetes who use insulin. The portfolio brings together insulin pumps, continuous glucose monitors, infusion sets and reservoirs, smart insulin pens, dosing algorithms, apps, and digital-care services. Revenue comes from reusable hardware and recurring sensors, supplies, software, and services sold to individuals, distributors, health-care providers, and institutions.
Serves pump users across an international footprint, with much of sales generated outside the United States and manufacturing in California and Puerto Rico. Its automated insulin-delivery systems combine a pump, compatible sensor, infusion set, reservoir, and dosing algorithm, while CareLink connects therapy data with patients, caregivers, and clinicians. Execution depends on safety and quality controls, reimbursement and distribution access, sole-source suppliers, Abbott’s sensor partnership, and transitional services from Medtronic, which retains voting control.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 2, 2026 | Deutsche Bank | Reiterate | Rating: —Target: — | Target: $25 |
| Sep 2, 2026 | Evercore ISI | Reiterate | Rating: —Target: — | Target: $27 |
| Sep 2, 2026 | UBS | Reiterate | Rating: —Target: $25 | Target: $28 |
| Sep 2, 2026 | Mizuho Securities | Target | Target: — | Target: $26 |
| Sep 2, 2026 | Wells Fargo | Reiterate | Rating: —Target: $26 | Target: $28 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 31, 2026Cash & short-term investments $207.0M · Total debt $59.0M · Total assets $4.72B · Shareholders' equity $3.62B
- Revenue
- $843.0M
- Operating income
- $38.0M
- Net income
- $0
No dividends on record.
| Institutions | ≈ 13.35% | 37.49M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Other | ≈ 86.65% | 243.35M shares | |
| remainder | |||
280.84M company shares as of Sep 10, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Massachusetts Financial Services Co /MA/Institution | 2.97% | 8.33M | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 1.09% | 3.06M | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 1.02% | 2.87M | as of Jun 30, 2026 |
Longaeva Partners L.P.Institution | 1.00% | 2.81M | as of Jun 30, 2026 |
Sessa Capital Im, L.P.Institution | 0.71% | 2.00M | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Dexcom
CGM choice competing for recurring sensor revenue.
- Insulet
Tubeless AID alternative to 780G and Flex.
- Tandem Diabetes Care
Tubed and compact AID alternatives with Control-IQ+.
- Beta Bionics
Algorithm-led iLet AID alternative for intensive insulin users.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MiniMed Group | $20.91 | −1.37% | $5.95B | — | 36.3 | 1.8 | — |
| Dexcom | $89.09 | −0.49% | $33.79B | 35.4 | 31.6 | 6.8 | +13.1% |
| Insulet | $138.55 | −0.60% | $9.65B | 26.1 | 20.1 | 3.2 | +23.5% |
| Tandem Diabetes Care | $17.01 | −2.80% | $1.20B | — | — | 1.2 | +5.8% |
| Beta Bionics | $22.70 | −0.48% | $1.03B | — | — | 8.6 | +37.8% |
| Median | 30.7 | 25.9 | 5.0 | +18.3% |